Arthritis Clinical Trials in Cincinnati
View 16 new treatments for Arthritis in Cincinnati, OH. Every day, Power helps hundreds of Arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Eli Lilly Clinic, Cincinnati + 1 more
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Adalimumab Discontinuation for Uveitis
Research Clinic, Cincinnati + 1 more
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).Show More
Waitlist
Phase 4
Est. 3 - 12 Weeks
Nisha Acharya, MD MS
Principal Investigator
Baricitinib for Rheumatoid Arthritis
Eli Lilly Clinic, Cincinnati + 1 more
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, Dayton + 2 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
David W Romness, MD
Principal Investigator
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Cincinnati + 1 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Axial Spondyloarthritis
AbbVie Clinic, Springboro + 1 more
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director
Tildrakizumab SC Injection for Psoriatic Arthritis
Sun Clinic, Cincinnati + 1 more
An open label phase 3 study
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Blue Ash + 3 more
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director
Secukinumab for Juvenile Arthritis
Novartis Clinic, Cincinnati + 2 more
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Novartis Pharmaceuticals
Study Director
Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis
Research Clinic, Liberty Township + 1 more
This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Jasvinder Singh, MD
Principal Investigator
Page 1 of 4
Frequently Asked Questions
Explore related conditions